Glioblastoma Treatment Market to Reach US$ 5.77 Billion by 2033 at 8.7% CAGR; North America Leads with 41.2% Share - Key Players: Merck & Co., Pfizer, Amgen, Novocure

The global glioblastoma treatment market reached US$ 2.98 billion in 2025 and is expected to reach US$ 5.77 billion by 2033, growing at a CAGR of 8.7% during the forecast period from 2026 to 2033. The market is experiencing significant growth driven by the rising incidence of aggressive brain cancers, increasing demand for advanced neuro oncology therapies, and continuous innovation in targeted treatment approaches. Growing adoption of precision medicine, immunotherapy, tumor treating fields (TTFields), and combination therapy regimens is supporting improved clinical management of glioblastoma patients worldwide. In addition, increasing investments in oncology research, expanding clinical trial pipelines, and advancements in blood brain barrier drug delivery technologies are further strengthening market expansion across major healthcare markets.

The market is also benefiting from recent regulatory approvals, orphan drug designations, and fast track development programs supporting innovative glioblastoma therapies. Companies such as Novocure, Roche, Bristol Myers Squibb, and Merck & Co. are actively advancing immuno oncology, targeted therapeutics, and next generation treatment platforms for recurrent and newly diagnosed glioblastoma. Furthermore, expanding reimbursement support, increasing access to specialized cancer treatment centers, and rising collaborations between biotechnology firms and research institutions are accelerating commercialization opportunities and improving market accessibility globally.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/glioblastoma-treatment-market?sai-v

Key Developments
February 2026: Increasing adoption of targeted therapies and immunotherapy combinations for glioblastoma treatment accelerated clinical research focused on improving survival outcomes and reducing tumor recurrence rates globally.

January 2026: Rising FDA fast track and orphan drug designations for novel glioblastoma therapeutics supported accelerated development of next generation cell therapies, oncolytic viruses, and precision oncology approaches.

December 2025: Growing integration of AI-based neuroimaging and molecular diagnostics improved early glioblastoma detection, treatment planning, and personalized therapy selection across major oncology centers.

November 2025: Expansion of clinical trials evaluating CAR-T cell therapies, tumor treating fields, and combination chemotherapy regimens strengthened innovation in advanced glioblastoma treatment pipelines worldwide.

October 2025: Increasing investments by biopharmaceutical companies in blood-brain barrier penetration technologies enhanced development of more effective drug delivery systems for glioblastoma therapeutics.

September 2025: Rising collaborations between academic research institutes and biotechnology companies accelerated discovery of novel biomarkers and gene-targeted therapies for recurrent and newly diagnosed glioblastoma patients.

August 2025: Growing adoption of minimally invasive neurosurgical procedures and precision radiotherapy technologies improved treatment accuracy and post-operative recovery outcomes in glioblastoma management.

July 2025: Increasing regulatory support for personalized cancer vaccines and RNA-based therapeutics strengthened commercialization opportunities for innovative glioblastoma treatment platforms globally.

June 2025: Rising focus on combination treatment strategies involving immunotherapy, radiation therapy, and chemotherapy improved progression-free survival rates and expanded therapeutic options for glioblastoma patients.

Key Players
Merck & Co., Inc. | Pfizer Inc. | Amneal Pharmaceuticals LLC | USWM, LLC. | Amgen Inc. | Day One Biopharmaceuticals, Inc. | Servier Pharmaceuticals LLC | Laminar Pharma | Sapience Therapeutics, Inc. | IN8bio Inc. | GT Medical Technologies, Inc. | Nanopharmaceutics, Inc. | Chimeric Therapeutics Ltd. | VBI Vaccines Inc. | Others

Key Highlights
Merck & Co., Inc. - Holds an estimated 15.2% share, driven by strong immuno-oncology capabilities, expanding pembrolizumab clinical programs in recurrent glioblastoma, and extensive oncology commercialization infrastructure.

Pfizer Inc. - Holds an estimated 11.4% share, supported by targeted therapy development, Hedgehog pathway inhibitor research, and broad global oncology distribution capabilities.

Amgen Inc. - Holds an estimated 10.8% share, fueled by biologic oncology expertise, advanced immunotherapy research initiatives, and expanding precision medicine investments in brain tumor therapies.

Amneal Pharmaceuticals LLC - Holds an estimated 7.3% share, driven by generic oncology drug manufacturing, increasing hospital distribution reach, and affordable chemotherapy product accessibility across emerging markets.

Servier Pharmaceuticals LLC - Holds an estimated 6.5% share, supported by expanding neuro-oncology portfolio strength, glioma-focused therapeutic development, and the acquisition of Day One Biopharmaceuticals to strengthen brain tumor treatment capabilities.

Day One Biopharmaceuticals, Inc. - Holds an estimated 5.1% share, powered by precision oncology pipeline expansion and commercialization of Ojemda for pediatric low-grade glioma treatment applications.

USWM, LLC. - Holds an estimated 4.2% share, driven by specialty pharmaceutical commercialization expertise and expanding neuro-oncology supportive care distribution capabilities across the U.S. market.

Laminar Pharma - Holds an estimated 2.8% share, supported by lipid-based therapeutic technology platforms and ongoing development of novel glioblastoma treatment candidates targeting tumor metabolism pathways.

IN8bio Inc. - Holds an estimated 2.3% share, fueled by gamma-delta T cell immunotherapy innovation and advancing clinical-stage cell therapy programs for glioblastoma treatment.

GT Medical Technologies, Inc. - Holds an estimated 1.9% share, driven by targeted radiation delivery systems, brachytherapy innovation, and localized treatment technologies for recurrent glioblastoma management.

Sapience Therapeutics, Inc. - Holds an estimated 1.6% share, supported by peptide-based oncology therapeutic research and early-stage glioblastoma-targeting treatment pipeline development.

Nanopharmaceutics, Inc. - Holds an estimated 1.3% share, powered by nanoparticle drug delivery research and blood-brain barrier penetration technologies for neuro-oncology applications.

Chimeric Therapeutics Ltd. - Holds an estimated 1.1% share, driven by CAR-T cell therapy development programs and expanding cell-based immunotherapy research targeting brain cancers.

VBI Vaccines Inc. - Holds an estimated 0.9% share, supported by immunotherapeutic vaccine development technologies and oncology-focused vaccine platform advancements for glioblastoma treatment research.

Others - Hold a combined estimated 27.6% share, comprising regional biotechnology companies, generic pharmaceutical manufacturers, and emerging oncology innovators advancing targeted therapy, immunotherapy, and precision neuro-oncology solutions globally.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=glioblastoma-treatment-market?sai-v

Market Drivers

Increasing global incidence of glioblastoma and rising prevalence of aggressive brain tumors are significantly driving demand for advanced therapeutic solutions and innovative treatment approaches.

Growing adoption of targeted therapies, immunotherapies, and precision medicine is accelerating the development of personalized glioblastoma treatment strategies worldwide.

Rising investments in neuro-oncology research, clinical trials, and next-generation cancer therapeutics are supporting continuous innovation in glioblastoma treatment pipelines.

Increasing regulatory approvals for novel therapies, drug-device combinations, and tumor treating field technologies are expanding treatment accessibility and improving patient management outcomes.

Growing demand for minimally invasive surgical procedures, advanced radiotherapy systems, and combination treatment regimens is strengthening the adoption of multimodal glioblastoma therapies.

Expansion of biomarker research and genomic profiling technologies is improving early diagnosis, treatment customization, and therapeutic response monitoring in glioblastoma patients.

Increasing healthcare expenditure, improving cancer care infrastructure, and rising awareness regarding brain tumor treatment options are further propelling market growth globally.

Industry Developments

Rapid advancement in immunotherapy and CAR-T cell therapy research improving therapeutic potential for recurrent and treatment-resistant glioblastoma cases.

Increasing adoption of tumor treating fields (TTF) technology enhancing survival outcomes when combined with standard chemotherapy and radiation therapy protocols.

Growing investments in AI-driven drug discovery and molecular profiling platforms accelerating development of targeted glioblastoma therapeutics.

Expansion of clinical trials evaluating oncolytic viruses, gene therapies, and nanoparticle-based drug delivery systems for enhanced brain tumor treatment efficacy.

Rising collaborations among biotechnology companies, pharmaceutical manufacturers, and research institutions supporting accelerated development of novel neuro-oncology therapies.

Strategic FDA designations and orphan drug approvals encouraging commercialization of innovative glioblastoma treatment candidates.

Continuous innovation in image-guided neurosurgery, precision radiotherapy, and blood-brain barrier penetration technologies improving treatment accuracy and patient outcomes.

Regional Insights

North America 41.2% share: "Leads the market due to advanced oncology infrastructure, strong presence of major pharmaceutical companies, high clinical trial activity, and increasing adoption of innovative glioblastoma therapies."

Europe 28.4% share: "Growth supported by expanding neuro-oncology research programs, favorable reimbursement systems, and increasing government support for rare cancer treatment development."

Asia Pacific 22.7% share: "Fastest-growing region driven by rising cancer incidence, improving healthcare infrastructure, expanding access to advanced therapies, and increasing investments in countries such as China, Japan, South Korea, and India."

Latin America 4.3% share: "Emerging growth supported by improving cancer diagnostics, rising awareness regarding brain tumor treatment, and gradual expansion of specialty oncology centers."

Middle East & Africa 3.4% share: "Gradual growth driven by increasing healthcare modernization initiatives, expanding oncology treatment access, and rising investments in advanced cancer care infrastructure."

Speak to our analyst and get customization in the report as per your requirements:https://www.datamintelligence.com/buy-now-page?report=glioblastoma-treatment-market?sai-v

Key Segments
➥ By Treatment Type

Chemotherapy: Represents the dominant segment, driven by widespread use of temozolomide-based regimens as the standard of care for newly diagnosed and recurrent glioblastoma patients.

Immunotherapy: Represents a rapidly growing segment, supported by increasing research into checkpoint inhibitors, cancer vaccines, CAR-T cell therapies, and personalized immune-based treatment approaches.

Electric-field Therapy: Represents a significant segment, fueled by growing adoption of tumor treating fields (TTF) technology for improving progression-free and overall survival in glioblastoma management.

Others: Represents an emerging segment, driven by ongoing development of targeted therapies, gene therapies, radiation sensitizers, and combination treatment strategies.

➥ By Type of Molecule

Small Molecules: Represents the dominant segment, supported by extensive use of oral chemotherapeutic agents and targeted therapies with favorable penetration across the blood-brain barrier.

Biologics: Represents a growing segment, fueled by increasing development of monoclonal antibodies, immunomodulators, and advanced biologic therapies for precision oncology applications.

➥ By Route of Administration

Oral: Represents the dominant segment, driven by high adoption of oral chemotherapy agents due to convenience, improved patient compliance, and long-term maintenance therapy usage.

Parenteral: Represents a significant segment, supported by increasing administration of biologics, injectable immunotherapies, and hospital-based supportive care treatments.

➥ By End-User

Hospitals: Represents the dominant segment, driven by rising hospitalization rates for glioblastoma treatment, availability of multidisciplinary oncology care, and access to advanced neuro-oncology infrastructure.

Clinics: Represents a growing segment, supported by increasing adoption of outpatient cancer treatment services, follow-up care, and specialized oncology consultation centers.

Others: Represents a moderate segment, fueled by growing utilization of ambulatory surgical centers, research institutes, and home-based supportive care services.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.